Showing results (1-10 of 1,368) with videos related to
Sort By:
Pageof 137
Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|March 7, 2024
[Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer]Chang Qi, Panwen Tian, Weimin LiZhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|July 14, 2021
[Progress of Liquid Biopsy in the Diagnosis and Treatment of Lung Cancer with Malignant Pleural Effusion]Hao Zeng, Panwen Tian, Weimin LiZhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|February 18, 2025
[Predictive Value of Prognostic Nutritional Index in Prognosis and Spontaneous Pleurodesis of Patients with Advanced Non-small Cell Lung Cancer and Malignant Pleural Effusion]Sihan Tan, Weimin Li, Panwen TianClinical and Experimental Medicine|July 18, 2024
Current status and progress of PD-L1 detection: guiding immunotherapy for non-small cell lung cancerChang Qi, Yalun Li, Hao Zeng, et al.Journal of Cancer Research and Clinical Oncology|July 19, 2018
Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trialsWenxin Luo, Zhoufeng Wang, Panwen Tian, et al.Frontiers in Oncology|August 22, 2025
Prognostic stratification through smoking status and cumulative smoking dose in advanced non-small cell lung cancer immunotherapy: a dose-dependent real-world analysisLan Yang, Haoyu Wang, Panwen Tian, et al.International Journal of Oncology|March 6, 2026
IL‑6: A key player in the EGFR‑TKI‑resistant tumor microenvironment and its therapeutic implications (Review)Qi Wei, Chengming Huang, Yuanyuan Zhang, et al.Cardiovascular Toxicology|September 10, 2024
Steroid-Refractory Myocarditis Induced by Immune Checkpoint Inhibitor Responded to Infliximab: Report of Two Cases and Literature ReviewSihan Tan, Chang Qi, Hao Zeng, et al.Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer|September 25, 2024
[Advances of Treatment of Pulmonary Large Cell Neuroendocrine Carcinoma]Jiayi Sun, Yawan Jing, Panwen Tian, et al.Frontiers in Oncology|March 31, 2023
Cost-effectiveness evaluation based on two models of first-line atezolizumab monotherapy and chemotherapy for advanced non-small cell lung cancer with high-PDL1 expressionChuan Zhang, Yue Liu, Jing Tan, et al.Pageof 137